SOURCE-LINKED STUDY SUMMARY
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Abstract summarizedQuality not appraised
- What was studied
- An animal experiment tested whether cardiolipin stabilization improves skeletal-muscle dysfunction in heart failure.
- Who / model studied
- Female rats: 24 with heart failure and preserved ejection fraction, plus 10 lean controls.
- Studied dose & schedule
- Heart-failure rats were randomized to elamipretide or saline for 12 weeks. Dose and route were not provided in the abstract.
- What the study found
- Elamipretide improved whole-muscle contractile function in soleus (+8.2%) and extensor digitorum longus (+10.9%), alongside less atrophy and improved mitochondrial measures.
- Limitations & context
- Abstract-based animal evidence. Restoration in diseased rats does not establish hypertrophy, exercise performance or safety benefits in healthy humans. Mechanistic associations do not prove mediation.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1161/CIRCHEARTFAILURE.126.014397